PACS
Neutral signalScored 2026-10-26 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
PACS Group, Inc.
- Nom
- PACS Group, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NYSE
- Capitalisation
- $7.6B
- Employés
- 47,455
- PDG
- Jason Murray
- Site web
- https://pacs.com
- Marché
- BKDCYHEHCENSGHCAINNV
PACS Group, Inc. operates as a holding company, primarily focused on delivering post-acute healthcare services. This encompasses operating various facilities, providing skilled professionals, and offering essential ancillary support. The company further specializes in providing a spectrum of senior living options, encompassing dedicated senior care, assisted living, and independent living residences in select communities. Founded in 2013 by Jason Murray and Mark Hancock, its corporate headquarters are located in Farmington, Utah.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 584 436 titres (~25 649 380,45 $ US)
- Insiders
- Murray Jason HulseHancock Mark
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$21,944,527
Avg sell (VWAP, 90d window) $44.37 vs last close $48.76 (+9.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$19,611,590 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-21
- Liquidity
- Liquid $41,174,285/day · 20d vol
- Last synced
-
2026-10-26 22:35:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-21 | Murray Jason Hulse | Sell · S | 6,610 | $47.62 | $314,755 | Form 4 |
| 2026-10-20 | Murray Jason Hulse | Sell · S | 37,477 | $47.65 | $1,785,820 | Form 4 |
| 2026-10-19 | Murray Jason Hulse | Sell · S | 1,620 | $47.57 | $77,060 | Form 4 |
| 2026-10-16 | Murray Jason Hulse | Sell · S · 10b5-1 | 8,462 | $47.61 | $402,876 | Form 4 |
| 2026-10-15 | Murray Jason Hulse | Sell · S · 10b5-1 | 3,062 | $48.11 | $147,298 | Form 4 |
| 2026-10-14 | Jergensen Joshua | Sell · S · 10b5-1 | 40,000 | $44.50 | $1,780,004 | Form 4 |
| 2026-10-14 | Murray Jason Hulse | Sell · S · 10b5-1 | 232 | $45.00 | $10,440 | Form 4 |
| 2026-10-07 | Murray Jason Hulse | Sell · S · 10b5-1 | 717 | $42.48 | $30,458 | Form 4 |
| 2026-10-06 | Murray Jason Hulse | Sell · S · 10b5-1 | 7,222 | $43.64 | $315,146 | Form 4 |
| 2026-10-05 | Murray Jason Hulse | Sell · S · 10b5-1 | 24,224 | $42.66 | $1,033,277 | Form 4 |
| 2026-10-02 | Murray Jason Hulse | Sell · S · 10b5-1 | 23,456 | $42.59 | $999,064 | Form 4 |
| 2026-10-01 | Murray Jason Hulse | Sell · S · 10b5-1 | 33,032 | $41.13 | $1,358,458 | Form 4 |
| 2026-09-16 | Jergensen Joshua | Sell · S · 10b5-1 | 3,498 | $43.62 | $152,576 | Form 4 |
| 2026-09-15 | Hancock Mark | Sell · S · 10b5-1 | 21,084 | $43.75 | $922,393 | Form 4 |
| 2026-09-14 | Hancock Mark | Sell · S · 10b5-1 | 6,634 | $44.91 | $297,901 | Form 4 |
| 2026-09-14 | Murray Jason Hulse | Sell · S · 10b5-1 | 317 | $45.03 | $14,275 | Form 4 |
| 2026-09-11 | Murray Jason Hulse | Sell · S · 10b5-1 | 10,529 | $45.23 | $476,190 | Form 4 |
| 2026-09-10 | Murray Jason Hulse | Sell · S · 10b5-1 | 8,771 | $45.16 | $396,105 | Form 4 |
| 2026-09-09 | Murray Jason Hulse | Sell · S · 10b5-1 | 4,758 | $43.33 | $206,147 | Form 4 |
| 2026-09-08 | Murray Jason Hulse | Sell · S · 10b5-1 | 21,001 | $43.59 | $915,530 | Form 4 |
| 2026-09-04 | Murray Jason Hulse | Sell · S · 10b5-1 | 243 | $43.14 | $10,484 | Form 4 |
| 2026-09-03 | Murray Jason Hulse | Sell · S · 10b5-1 | 858 | $43.11 | $36,987 | Form 4 |
| 2026-09-02 | Murray Jason Hulse | Sell · S · 10b5-1 | 6,348 | $43.36 | $275,274 | Form 4 |
| 2026-09-01 | Murray Jason Hulse | Sell · S · 10b5-1 | 1,368 | $43.05 | $58,890 | Form 4 |
| 2026-08-21 | Murray Jason Hulse | Sell · S · 10b5-1 | 27,590 | $44.25 | $1,220,772 | Form 4 |
| 2026-08-20 | Murray Jason Hulse | Sell · S · 10b5-1 | 13,879 | $44.76 | $621,259 | Form 4 |
| 2026-08-19 | Murray Jason Hulse | Sell · S · 10b5-1 | 67 | $44.85 | $3,005 | Form 4 |
| 2026-08-18 | Murray Jason Hulse | Sell · S · 10b5-1 | 66,797 | $44.18 | $2,951,138 | Form 4 |
| 2026-08-17 | Murray Jason Hulse | Sell · S · 10b5-1 | 74,844 | $44.27 | $3,313,374 | Form 4 |
| 2026-08-14 | Conway Patrick Hugh | Sell · S | 3,497 | $44.41 | $155,302 | Form 4 |
| 2026-08-12 | Jergensen Joshua | Sell · S · 10b5-1 | 36,375 | $45.70 | $1,662,268 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-26 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
PACS displays genuine operational improvement with expanding margins and a declining leverage ratio, but the very low catalyst score (25) driven by heavy insider selling of $25M+ by the CEO and others in October 2026 is…
The first sentence of the analysis written for PACS on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 1.07 · operating margin 5.9%
Suggested stop 44.13, nearest stored support minus 0.5 ATR(9.5% under the last close). Reward/risk to the next stored resistance is 0.16. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-23 Cantor Fitzgerald Investment Advisors L.P. Makes New Investment in PACS Group, Inc. $PACS Cantor Fitzgerald Investment Advisors L.P. bought a new stake in PACS Group, Inc. (NYSE: PACS) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 46,200 shares of the company''s stock, valued at approximately $1,920,000. Other institutional investors
- 2026-10-19 Insider Selling: PACS Group (NYSE:PACS) CEO Sells $10,440.00 in Stock PACS Group, Inc. (NYSE: PACS - Get Free Report) CEO Jason Murray sold 232 shares of the business''s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $45.00, for a total transaction of $10,440.00. Following the completion of the transaction, the chief executive officer directly owned 54,435,017 shares
- 2026-10-19 PACS Group (NYSE:PACS) CEO Sells $402,875.82 in Stock PACS Group, Inc. (NYSE: PACS - Get Free Report) CEO Jason Murray sold 8,462 shares of PACS Group stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $47.61, for a total value of $402,875.82. Following the transaction, the chief executive officer directly owned 54,316,520 shares in the company,
- 2026-10-18 PACS Group (NYSE:PACS) Stock: Insider Jason Hulse Murray Sells 110,035 Shares PACS Group, Inc. (NYSE: PACS - Get Free Report) CEO Jason Murray sold 110,035 shares of PACS Group stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $47.27, for a total value of $5,201,354.45. Following the transaction, the chief executive officer directly owned 54,324,982 shares in
- 2026-10-16 PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains? PACS Group, Inc. (PACS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 2026-10-13 PACS Group, Inc. (NYSE:PACS) Stock Rated “Moderate Buy” by Wall Street Brokerages PACS Group, Inc. (NYSE: PACS - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month
- 2026-10-08 PACS Group (NYSE:PACS) CEO Jason Hulse Murray Sells 717 Shares of Stock PACS Group, Inc. (NYSE: PACS - Get Free Report) CEO Jason Murray sold 717 shares of PACS Group stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $42.48, for a total value of $30,458.16. Following the completion of the transaction, the chief executive officer owned 54,435,249 shares in
- 2026-10-05 Omega to Transition Operations of 32 Facilities in Florida to PACS Group HUNT VALLEY, Md.--(BUSINESS WIRE)---- $OHI #Healthcare--Omega Healthcare Investors, Inc. (NYSE: OHI) (the “Company” or “Omega”) today announced that it transitioned 32 skilled nursing facilities in Florida from an operator managed by affiliates of Airamid Health Services, LLC (“Airamid”) to subsidiaries of PACS Group, Inc. (NYSE: PACS) (“PACS”). The effective date of the transition was October 1, 2026.In conjunction with this transition, rent on this portfolio is scheduled to increase by $26.1 million in year one an.
- 2026-09-30 Seventeen PACS Post-Acute Locations Named Top Nursing Homes for 2027 by Newsweek Magazine SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS”) is proud to announce that 17 of its post-acute communities have been named by Newsweek Magazine to its list of Best Nursing Homes for 2027. Those communities are as follows, listed in order by their state, and then their ranking in their state by category: Community Name State Ranking Category Ridgecrest Post Acute Arizona 9th Large (150+ beds) Paradise Valley Manor and Health Care Center California 14th Small (50-9.
- 2026-09-26 Did PACS Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did PACS Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 25, 2026Shareholders are encouraged to contact the firm t
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 21.9% | 19.4% | 14.4% | 16.5% | 16.1% | |
| Ebit Margin | 5.9% | 3.6% | 6.7% | 9.6% | 7.4% | |
| Ebitda Margin | 6.9% | 4.6% | 7.5% | 10.5% | 8.0% | |
| Operating Profit Margin | 5.9% | 3.0% | 6.7% | 9.5% | 7.1% | |
| Pretax Profit Margin | 5.4% | 2.5% | 5.1% | 8.5% | 7.0% | |
| Continuous Operations Profit Margin | 3.6% | 1.4% | 3.6% | 6.2% | 4.1% | |
| Net Profit Margin | 3.6% | 1.4% | 3.6% | 6.2% | 4.1% | |
| Bottom Line Profit Margin | 3.6% | 1.4% | 3.6% | 6.2% | 4.1% | |
| Current Ratio | 1.068 | 0.959 | 1.580 | 1.056 | 0.000 | |
| Quick Ratio | 1.068 | 0.959 | 1.580 | 1.056 | 0.000 | |
| Solvency Ratio | 0.053 | 0.021 | 0.041 | 0.072 | 0.000 | |
| Cash Ratio | 0.197 | 0.161 | 0.161 | 0.120 | 0.000 | |
| Price To Earnings Ratio | 31.211 | 34.500 | 30.667 | 23.000 | 71.875 | |
| Price To Earnings Growth Ratio | 0.140 | -0.699 | -1.227 | 0.108 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.140 | -0.699 | -1.227 | 0.108 | 0.000 | |
| Price To Earnings Diluted Ratio | 31.467 | 34.500 | 30.667 | 23.000 | 71.875 | |
| Price To Earnings Diluted Growth Ratio | 0.142 | -0.699 | -1.227 | 0.108 | 0.000 | |
| Price To Book Ratio | 6.333 | 2.710 | 35.927 | 54.261 | 0.000 | |
| Price To Sales Ratio | 1.134 | 0.470 | 1.110 | 1.426 | 2.960 | |
| Price To Free Cash Flow Ratio | 20.065 | 109.671 | 192.771 | 49.510 | -51.944 | |
| Price To Operating Cash Flow Ratio | 14.833 | 5.234 | 54.218 | 37.289 | 59.954 | |
| Debt To Assets Ratio | 0.622 | 0.668 | 0.798 | 0.782 | 0.000 | |
| Debt To Equity Ratio | 3.666 | 4.934 | 29.179 | 30.254 | 0.000 | |
| Debt To Capital Ratio | 0.786 | 0.831 | 0.967 | 0.968 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.267 | 0.261 | 0.882 | 0.873 | 0.000 | |
| Financial Leverage Ratio | 5.898 | 7.389 | 36.543 | 38.681 | 0.000 | |
| Working Capital Turnover Ratio | 375.928 | 36.345 | 21.274 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | 0.404 | 0.375 | 0.139 | 0.191 | 0.000 | |
| Operating Cash Flow Sales Ratio | 0.076 | 0.090 | 0.020 | 0.038 | 0.049 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.739 | 0.048 | 0.281 | 0.753 | -1.154 | |
| Debt Service Coverage Ratio | 8.304 | 0.698 | 2.823 | 2.282 | 0.000 | |
| Interest Coverage Ratio | 10.915 | 2.776 | 4.162 | 8.981 | 15.794 | |
| Short Term Operating Cash Flow Coverage Ratio | 90.572 | 2.342 | 3.787 | 1.509 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.116 | 0.105 | 0.023 | 0.048 | 0.000 | |
| Capital Expenditure Coverage Ratio | 3.835 | 1.050 | 1.391 | 4.051 | 0.464 | |
| Dividend Paid And Capex Coverage Ratio | 3.835 | 0.958 | 0.505 | 1.114 | 0.324 | |
| Dividend Payout Ratio | 0.000 | 0.605 | 0.712 | 0.401 | 1.122 | |
| Enterprise Value Multiple | 25.357 | 28.206 | 26.560 | 20.874 | 0.000 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 21.9% | ▲2.5% | ▲4.3% |
| Ebit Margin | 5.9% | ▲2.3% | ▼-0.8% |
| Ebitda Margin | 6.9% | ▲2.4% | ▼-0.6% |
| Operating Profit Margin | 5.9% | ▲2.8% | ▼-0.6% |
| Pretax Profit Margin | 5.4% | ▲2.9% | ▼-0.3% |
| Continuous Operations Profit Margin | 3.6% | ▲2.3% | ▼-0.2% |
| Net Profit Margin | 3.6% | ▲2.3% | ▼-0.2% |
| Bottom Line Profit Margin | 3.6% | ▲2.3% | ▼-0.2% |
| Current Ratio | 1.068 | ▲0.109 | ▲0.135 |
| Quick Ratio | 1.068 | ▲0.109 | ▲0.135 |
| Solvency Ratio | 0.053 | ▲0.032 | ▲0.016 |
| Cash Ratio | 0.197 | ▲0.036 | ▲0.069 |
| Price To Earnings Ratio | 31.211 | ▼-3.289 | ▼-7.039 |
| Price To Earnings Growth Ratio | 0.140 | ▲0.839 | ▲0.475 |
| Forward Price To Earnings Growth Ratio | 0.140 | ▲0.839 | ▲0.475 |
| Price To Earnings Diluted Ratio | 31.467 | ▼-3.033 | ▼-6.835 |
| Price To Earnings Diluted Growth Ratio | 0.142 | ▲0.842 | ▲0.477 |
| Price To Book Ratio | 6.333 | ▲3.623 | ▼-13.513 |
| Price To Sales Ratio | 1.134 | ▲0.663 | ▼-0.286 |
| Price To Free Cash Flow Ratio | 20.065 | ▼-89.606 | ▼-43.950 |
| Price To Operating Cash Flow Ratio | 14.833 | ▲9.599 | ▼-19.473 |
| Debt To Assets Ratio | 0.622 | ▼-0.046 | ▲0.048 |
| Debt To Equity Ratio | 3.666 | ▼-1.268 | ▼-9.941 |
| Debt To Capital Ratio | 0.786 | ▼-0.046 | ▲0.075 |
| Long Term Debt To Capital Ratio | 0.267 | ▲0.006 | ▼-0.190 |
| Financial Leverage Ratio | 5.898 | ▼-1.491 | ▼-11.804 |
| Working Capital Turnover Ratio | 375.928 | ▲339.583 | ▲289.219 |
| Operating Cash Flow Ratio | 0.404 | ▲0.028 | ▲0.182 |
| Operating Cash Flow Sales Ratio | 0.076 | ▼-0.013 | ▲0.022 |
| Free Cash Flow Operating Cash Flow Ratio | 0.739 | ▲0.692 | ▲0.606 |
| Debt Service Coverage Ratio | 8.304 | ▲7.605 | ▲5.482 |
| Interest Coverage Ratio | 10.915 | ▲8.140 | ▲2.390 |
| Short Term Operating Cash Flow Coverage Ratio | 90.572 | ▲88.230 | ▲70.930 |
| Operating Cash Flow Coverage Ratio | 0.117 | ▲0.011 | ▲0.058 |
| Capital Expenditure Coverage Ratio | 3.835 | ▲2.785 | ▲1.677 |
| Dividend Paid And Capex Coverage Ratio | 3.835 | ▲2.877 | ▲2.488 |
| Dividend Payout Ratio | 0.000 | ▼-0.605 | ▼-0.568 |
| Enterprise Value Multiple | 25.358 | ▼-2.848 | ▲5.158 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.00B | $1.92B | $3.45B | $3.45B | $3.45B | |
| Enterprise value | $9.27B | $5.27B | $6.18B | $5.32B | $0 | |
| EV / Sales | 1.75x | 1.29x | 1.99x | 2.20x | 0.00x | |
| EV / Op. cash flow | 22.93x | 14.34x | 97.10x | 57.45x | 0.00x | |
| EV / Free cash flow | 31.02x | 300.37x | 345.24x | 76.28x | 0.00x | |
| EV / EBITDA | 25.36x | 28.21x | 26.56x | 20.87x | 0.00x | |
| Net debt / EBITDA | 8.96x | 17.91x | 11.73x | 7.33x | 0.00x | |
| Current ratio | 1.07x | 0.96x | 1.58x | 1.06x | 0.00x | |
| Income quality | 2.11x | 6.59x | 0.56x | 0.61x | 1.20x | |
| Graham number | $13 | $6 | $3 | $3 | $0 | |
| Graham net-net | -$25 | -$26 | -$19 | -$13 | $0 | |
| Tax burden | 67.3% | 54.9% | 71.7% | 72.7% | 58.9% | |
| Interest burden | 91.8% | 69.6% | 75.9% | 89.0% | 93.9% | |
| Working capital | $68.3M | -$40.2M | $265.2M | $27.3M | $0 | |
| Invested capital | $4.31B | $4.01B | $2.92B | $1.86B | $0 | |
| Return on assets | 3.4% | 1.1% | 3.2% | 6.1% | 0.0% | |
| Operating ROA | 5.7% | 2.8% | 7.0% | 0.0% | 0.0% | |
| Return on tangible assets | 3.5% | 1.1% | 3.3% | 6.3% | 0.0% | |
| Return on equity | 20.2% | 7.9% | 117.4% | 236.5% | 0.0% | |
| Return on invested capital | 4.4% | 1.5% | 4.7% | 7.7% | 0.0% | |
| Return on capital employed | 6.8% | 2.9% | 6.8% | 11.6% | 0.0% | |
| Earnings yield | 3.2% | 2.9% | 3.3% | 4.4% | 1.4% | |
| Free cash flow yield | 5.0% | 0.9% | 0.5% | 2.0% | -1.9% | |
| Capex / Op. cash flow | 26.1% | 95.2% | 71.9% | 24.7% | 215.4% | |
| Capex / Depreciation | 189.4% | 857.2% | 178.6% | 102.5% | 1734.8% | |
| Capex / Sales | 2.0% | 8.6% | 1.5% | 0.9% | 10.6% | |
| SG&A / Sales | 7.8% | 8.4% | 6.9% | 6.2% | 8.3% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.0% | 2.8% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 1.2% | 1.3% | 1.9% | 2.5% | 0.0% | |
| Days sales outstanding | 48d | 64d | 70d | 63d | 0d | |
| Days payables outstanding | 17d | 19d | 19d | 20d | 0d | |
| Operating cycle | 48d | 64d | 70d | 63d | 0d | |
| Cash conversion cycle | 31d | 45d | 51d | 43d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+211.8%EV / Sales ▲+36.1%EV / EBITDA ▼-10.1%EV / Op. cash flow ▲+8.597Earnings yield ▲+0.003Graham number ▲+6.500
Profitability
Return on equity ▲+0.124Return on assets ▲+0.024Return on invested capital ▲+0.029Return on capital employed ▲+0.039Operating ROA ▲+0.029Income quality ▼-4.477Tax burden ▲+0.124
Efficiency
Days sales outstanding ▼-15.495Days payables outstanding ▼-2.390Operating cycle ▼-15.495Cash conversion cycle ▼-13.105Capex / Sales ▼-0.066R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.109Net debt / EBITDA ▼-8.951Working capital ▲+108480000.000Invested capital ▲+293653000.000Intangibles / Total assets ▼-0.001
Change over 5 years
Valuation
Market cap ▲+73.6%EV / Sales n/aEV / EBITDA n/aEV / Op. cash flow n/aEarnings yield ▲+0.018Graham number n/a
Profitability
Return on equity n/aReturn on assets n/aReturn on invested capital n/aReturn on capital employed n/aOperating ROA n/aIncome quality ▲+0.910Tax burden ▲+0.085
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-0.086R&D / Sales n/a
Balance-sheet strength
Current ratio n/aNet debt / EBITDA n/aWorking capital n/aInvested capital n/aIntangibles / Total assets n/a